Who are acetam/ketoro tromet group's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Maxigesic IV, Combogesic® tablets.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/acetam-ketoro-tromet-group.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

acetam/ketoro tromet group — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

acetam/ketoro tromet group (acetam/ketoro tromet group) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fixed-dose combination analgesic/NSAID. Area: Pain Management.

phase 3 Fixed-dose combination analgesic/NSAID Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

acetam/ketoro tromet group (acetam/ketoro tromet group) — Universidade Estadual de Ponta Grossa. This combination drug likely combines acetaminophen's analgesic and antipyretic effects with ketoprofen's nonsteroidal anti-inflammatory properties, potentially enhanced by trometamol as a buffering agent for improved tolerability.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
acetam/ketoro tromet group TARGET	acetam/ketoro tromet group	Universidade Estadual de Ponta Grossa	phase 3	Fixed-dose combination analgesic/NSAID
Maxigesic IV	Maxigesic IV	AFT Pharmaceuticals, Ltd.	phase 3	Fixed-dose combination analgesic/NSAID	Prostaglandin synthesis inhibitors (COX-1, COX-2, and central pain pathways)
Combogesic® tablets	Combogesic® tablets	AFT Pharmaceuticals, Ltd.	phase 3	Fixed-dose combination analgesic/NSAID	COX-1, COX-2 (ibuprofen); central pain pathways (paracetamol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fixed-dose combination analgesic/NSAID class)

AFT Pharmaceuticals, Ltd. · 2 drugs in this class
Universidade Estadual de Ponta Grossa · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). acetam/ketoro tromet group — Competitive Intelligence Brief. https://druglandscape.com/ci/acetam-ketoro-tromet-group. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab